Matches in SemOpenAlex for { <https://semopenalex.org/work/W3084555372> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W3084555372 endingPage "1496" @default.
- W3084555372 startingPage "1491" @default.
- W3084555372 abstract "Abstract Introduction Hyperprogression, characterized by a rapid acceleration in tumor growth, is a novel pattern of progression recently described in patients treated with immune checkpoint inhibitors. This study aims to assess the incidence of hyperprogression in patients with advanced melanoma treated with checkpoint inhibitors. Methods Clinical and radiological findings of all advanced melanoma patients who started checkpoint inhibitors between January 2013 and March 2019 in a tertiary academic center in the Netherlands were analyzed. Change in tumor burden was calculated by assessing volumetric tumor growth using the criteria as defined by immune Response Evaluation Criteria in Solid Tumors version 1.1. Hyperprogression was defined as a time to treatment failure less than 2 months with doubling of tumor burden and a twofold increase in tumor growth rate during treatment. Possible hyperprogression was defined as the presence of the first two criteria in the absence of a pre-baseline scan. Results Out of 206 treatment episodes in 168 patients, 75 were evaluable for hyperprogression and 87 for possible hyperprogression. Hyperprogression was observed in one patient (1.3%) and possible hyperprogression was observed in one patient (1.1%). Conclusion Hyperprogression is rare in melanoma patients treated with immune checkpoint inhibitors. Our data question if hyperprogression really is a biological entity in metastatic melanoma." @default.
- W3084555372 created "2020-09-21" @default.
- W3084555372 creator A5006651390 @default.
- W3084555372 creator A5058399030 @default.
- W3084555372 creator A5087767413 @default.
- W3084555372 creator A5014113499 @default.
- W3084555372 date "2020-09-14" @default.
- W3084555372 modified "2023-10-15" @default.
- W3084555372 title "Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma" @default.
- W3084555372 cites W2019607817 @default.
- W3084555372 cites W2097995306 @default.
- W3084555372 cites W2154196978 @default.
- W3084555372 cites W2554618897 @default.
- W3084555372 cites W2592144107 @default.
- W3084555372 cites W2768557781 @default.
- W3084555372 cites W2891266481 @default.
- W3084555372 cites W2891951654 @default.
- W3084555372 cites W2896600825 @default.
- W3084555372 cites W2909349708 @default.
- W3084555372 cites W2909887958 @default.
- W3084555372 cites W2935797142 @default.
- W3084555372 cites W2941582519 @default.
- W3084555372 cites W2946105993 @default.
- W3084555372 cites W2951285627 @default.
- W3084555372 cites W3009008277 @default.
- W3084555372 cites W3033353648 @default.
- W3084555372 cites W4214886288 @default.
- W3084555372 doi "https://doi.org/10.1007/s00262-020-02716-3" @default.
- W3084555372 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8053186" @default.
- W3084555372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32929554" @default.
- W3084555372 hasPublicationYear "2020" @default.
- W3084555372 type Work @default.
- W3084555372 sameAs 3084555372 @default.
- W3084555372 citedByCount "14" @default.
- W3084555372 countsByYear W30845553722021 @default.
- W3084555372 countsByYear W30845553722022 @default.
- W3084555372 countsByYear W30845553722023 @default.
- W3084555372 crossrefType "journal-article" @default.
- W3084555372 hasAuthorship W3084555372A5006651390 @default.
- W3084555372 hasAuthorship W3084555372A5014113499 @default.
- W3084555372 hasAuthorship W3084555372A5058399030 @default.
- W3084555372 hasAuthorship W3084555372A5087767413 @default.
- W3084555372 hasBestOaLocation W30845553721 @default.
- W3084555372 hasConcept C120665830 @default.
- W3084555372 hasConcept C121332964 @default.
- W3084555372 hasConcept C121608353 @default.
- W3084555372 hasConcept C126322002 @default.
- W3084555372 hasConcept C143998085 @default.
- W3084555372 hasConcept C2777658100 @default.
- W3084555372 hasConcept C2777701055 @default.
- W3084555372 hasConcept C2779134260 @default.
- W3084555372 hasConcept C2780057760 @default.
- W3084555372 hasConcept C2780851360 @default.
- W3084555372 hasConcept C2994587330 @default.
- W3084555372 hasConcept C502942594 @default.
- W3084555372 hasConcept C61511704 @default.
- W3084555372 hasConcept C71924100 @default.
- W3084555372 hasConceptScore W3084555372C120665830 @default.
- W3084555372 hasConceptScore W3084555372C121332964 @default.
- W3084555372 hasConceptScore W3084555372C121608353 @default.
- W3084555372 hasConceptScore W3084555372C126322002 @default.
- W3084555372 hasConceptScore W3084555372C143998085 @default.
- W3084555372 hasConceptScore W3084555372C2777658100 @default.
- W3084555372 hasConceptScore W3084555372C2777701055 @default.
- W3084555372 hasConceptScore W3084555372C2779134260 @default.
- W3084555372 hasConceptScore W3084555372C2780057760 @default.
- W3084555372 hasConceptScore W3084555372C2780851360 @default.
- W3084555372 hasConceptScore W3084555372C2994587330 @default.
- W3084555372 hasConceptScore W3084555372C502942594 @default.
- W3084555372 hasConceptScore W3084555372C61511704 @default.
- W3084555372 hasConceptScore W3084555372C71924100 @default.
- W3084555372 hasIssue "5" @default.
- W3084555372 hasLocation W30845553721 @default.
- W3084555372 hasLocation W30845553722 @default.
- W3084555372 hasOpenAccess W3084555372 @default.
- W3084555372 hasPrimaryLocation W30845553721 @default.
- W3084555372 hasRelatedWork W1703213295 @default.
- W3084555372 hasRelatedWork W2607780130 @default.
- W3084555372 hasRelatedWork W2765472296 @default.
- W3084555372 hasRelatedWork W2777867648 @default.
- W3084555372 hasRelatedWork W2903811712 @default.
- W3084555372 hasRelatedWork W2967217932 @default.
- W3084555372 hasRelatedWork W3118180598 @default.
- W3084555372 hasRelatedWork W3138290406 @default.
- W3084555372 hasRelatedWork W3193367738 @default.
- W3084555372 hasRelatedWork W4292373623 @default.
- W3084555372 hasVolume "70" @default.
- W3084555372 isParatext "false" @default.
- W3084555372 isRetracted "false" @default.
- W3084555372 magId "3084555372" @default.
- W3084555372 workType "article" @default.